184 related articles for article (PubMed ID: 33173309)
1. A Novel
Sun Y; Pei L; Luo N; Chen D; Meng L
Onco Targets Ther; 2020; 13():11177-11181. PubMed ID: 33173309
[TBL] [Abstract][Full Text] [Related]
2. Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report.
Wang X; Peng W; Zeng Z; Cai J; Liu A
Front Oncol; 2021; 11():720819. PubMed ID: 35004270
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
[TBL] [Abstract][Full Text] [Related]
4. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
Zeng Y; Feng Y; Fu G; Jiang J; Liu X; Pan Y; Hu C; Liu X; Wu F
Front Pharmacol; 2022; 13():838247. PubMed ID: 35462930
[TBL] [Abstract][Full Text] [Related]
5. Two case reports of non-small cell lung cancer patients harboring acquired
Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
[TBL] [Abstract][Full Text] [Related]
6.
Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
[TBL] [Abstract][Full Text] [Related]
7. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
8. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
9. NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma.
Li D; Yang D; Cui S; Pan E; Yang P; Dai Z
Onco Targets Ther; 2021; 14():4261-4265. PubMed ID: 34321891
[TBL] [Abstract][Full Text] [Related]
10. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
[TBL] [Abstract][Full Text] [Related]
11. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
12. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M,
Chang Y; Liu S; Jiang Y; Hua L; Wen L
Respir Med Case Rep; 2022; 36():101582. PubMed ID: 35106279
[TBL] [Abstract][Full Text] [Related]
15.
Ma L; Chen R; Wang F; Ma LL; Yuan MM; Chen RR; Liu J
Ann Transl Med; 2019 May; 7(9):207. PubMed ID: 31205925
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
17.
Kong WM; Guo YJ; Ma J; Shi C
Transl Cancer Res; 2023 Jan; 12(1):186-193. PubMed ID: 36760378
[TBL] [Abstract][Full Text] [Related]
18. Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in
Liao BC; Hsu WH; Lee JH; Yang CY; Tsai TH; Liao WY; Ho CC; Lin CC; Shih JY; Yu CJ; Soo RA; Yang JC
JTO Clin Res Rep; 2021 Jan; 2(1):100099. PubMed ID: 34589970
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
Saad N; Poudel A; Basnet A; Gajra A
Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
[TBL] [Abstract][Full Text] [Related]
20.
Buder A; Hochmair MJ; Setinek U; Pirker R; Filipits M
Transl Lung Cancer Res; 2020 Apr; 9(2):239-245. PubMed ID: 32420063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
